AliveCor is a digital health company that develops portable, FDA-cleared personal electrocardiogram (ECG) devices and AI-powered software for heart monitoring.[1][2][5] Its flagship Kardia product line—including KardiaMobile (single-lead), KardiaMobile 6L (six-lead), Kardia 12L (portable 12-lead), and KardiaMobile Card—serves consumers, healthcare providers, health systems, and OEM partners by detecting arrhythmias like atrial fibrillation, bradycardia, and tachycardia in seconds.[1][3][5][7] The company solves the problem of inaccessible cardiac monitoring by enabling anytime, anywhere heart data collection outside clinics, with enterprise tools like KardiaPro and KardiaComplete supporting remote patient management and clinical trials.[2][3] AliveCor's growth is evidenced by over a decade of clinical validation, partnerships with wearables manufacturers, and adoption by millions of patients and providers worldwide.[1][3][4]
AliveCor was founded by Dr. David E. Albert, a physician and inventor specializing in medical technology, with the vision of making medical-grade ECGs accessible to everyone via smartphones.[1] The idea emerged from combining clinical expertise with digital innovation, leading to early products like the KardiaMobile, one of the most validated personal ECG devices.[1][5] Pivotal moments include FDA clearances for its devices, the launch of the first portable 12-lead ECG (Kardia 12L), and expansion into AI-driven analysis for broader arrhythmia detection, evolving from consumer tools to comprehensive enterprise platforms over more than 10 years.[1][3][7]
AliveCor rides the wave of AI-driven remote patient monitoring and consumer wearables amid rising cardiovascular disease prevalence—the leading global cause of death—enabling proactive care beyond hospitals.[2][3][4] Timing aligns with post-pandemic demand for telehealth and decentralized trials, where portable ECGs provide medical-grade insights faster than traditional methods, enhancing efficiency for overburdened providers.[3] Market forces like FDA approvals, AI advancements, and integrations with health systems favor AliveCor, influencing the ecosystem by setting standards for personal cardiology tech and partnering with OEMs to embed ECG in everyday devices.[1][4][7]
AliveCor is poised to expand its AI cardiology platform with next-gen devices like KardiaMobile 6L Max and deeper OEM integrations, capitalizing on personalized medicine trends.[5][9] Evolving regulations for AI diagnostics and growth in value-based care will shape its path, potentially amplifying influence through broader health system adoption and global wearables penetration. As cardiovascular risks persist, AliveCor's mission to deliver actionable heart data anytime positions it as a leader in transforming proactive cardiac care.[2]
AliveCor has raised $11.0M in total across 1 funding round.
AliveCor has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Series B in June 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2012 | $11.0M Series B |
